Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background and Objectives: We analyzed the correlations between pretreatment serum levels of 11 cytokines and soluble cytokine receptors (interleukin 6 (IL‐6); interleukin 8 (IL‐8); interleukin 10 (IL‐10); vascular endothelial growth factor (VEGF); basic fibroblast growth factor (bFGF); macrophage colony‐stimulating factor (M‐CSF); granulocyte colony‐stimulating factor (G‐CSF); interleukin 1 receptor antagonist (IL‐1ra); sIL‐2Rα; tumor necrosis factor receptor I (TNF RI), and TNF RII) with clinico‐pathological features and survival of patients with bone sarcomas. Methods: Altogether, 72 patients with bone sarcomas without distant metastases before treatment (26 osteosarcomas‐36%, 23 chondrosarcomas‐32%, 13 Ewing's sarcomas/PNET‐18%, 10 giant‐cell tumors‐14%), 22 patients with benign non‐inflammatory bone tumors and 50 age‐matched healthy controls were included into this prospective study. Results: Median serum levels of 9/11 cytokines, with the exception of sIL‐2Rα and G‐CSF, were significantly higher in sarcoma patients than in controls. Median serum levels of IL‐6, IL‐8, IL‐1ra, TNF RI, and M‐CSF were significantly higher in patients with bone sarcoma as compared to patients with benign bone tumors. In 45.9% of sarcoma patients, six or more cytokines and cytokine receptors, including those that are involved in bone destruction (e.g., IL‐6 and IL‐8) and bone formation (e.g., IL‐1ra and TNFRI and TNFRII), were elevated in parallel. Serum levels of IL‐6, IL‐8, TNF RI, TNF RII, and VEGF correlated significantly with tumor size (<10 cm vs. ≥10 cm in diameter) and serum levels of IL‐6, IL‐8, TNF RI, and IL‐1ra correlated significantly with local tumor extent (E2/4 vs. E5/6 according to the classification proposed by Spanier et al. 46). Moreover, serum levels of IL‐1ra and IL‐6 were significantly higher in patients with small tumors (<5 cm in diameter) infiltrating structures adjacent to the periosteum (E5/6) than in large tumors (>10 cm in diameter) but confined to the bone and periosteum (E < 4). The lowest median serum levels of 8/11 cytokines/cytokine receptors were found in patients with giant‐cell tumors. In an univariate analysis, increased serum levels of IL‐1ra, IL‐6, IL‐8, IL‐10, sIL‐2Rα, M‐CSF, TNF RI, and TNF RII, the number of cytokines elevated, higher tumor grade, larger tumor size, greater local extent (E) and patients' age >35 years correlated with poor overall survival (OS) (P < 0.05). Similarly, high serum levels of IL‐1ra, IL‐6, TNF RI and TNF RII, tumor grade, tumor size, and tumor local extent (E) (P < 0.05) affected disease free survival (DFS) in univariate analysis. Multivariate analysis using Cox's proportional hazards model showed that high serum levels of IL‐1ra (P = 0.039) and TNF RI (P = 0.048), the number of serum cytokines above normal cut‐off values (0–1 vs. 2–5 vs. ≥6; P = 0.029), greater tumor local extent E (E2/4 vs. E5/6; P = 0.02) correlated significantly with shorter OS. Only E was found as an independent prognostic factor for DFS (P = 0.04). Conclusions: These findings indicate that cytokines and soluble cytokine receptors, both physiologically involved in bone destruction and bone formation, have an essential role in the progression of malignant bone tumors. J. Surg. Oncol. 2003;84:151–159. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
Pacifici, R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110802 · Cited by 741
Cited by
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 474
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., & Suda, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081605 · Cited by 388
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., & Khanna, C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-625 · Cited by 291
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Sanmamed, M. F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín-Algarra, S., Perez, G., Landazuri, S. F., Gonzalez, Á., Gross, S., Rodriguez, I., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3203 · Cited by 256
Lippitz, B. E., & Harris, R. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1093722 · Cited by 248
The dual role of IL-6-type cytokines on bone remodeling and bone tumors
Blanchard, F., Duplomb, L., Baud’huin, M., & Brounais, B. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.004 · Cited by 218
“Patients with osteosarcoma, chondrosarcoma, Ewing’s sarcoma, giant cell tumor of bone [57], melanoma [58] and breast cancer [55] have significant elevated levels of serum IL-6, in correlation with a poor overall survival.”
BackgroundBlocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187
“serum levels compared with control individuals (55, 56), and sustain activated intra-tumor STAT3 signaling as we demonstrate in this study (Fig.”
BackgroundCommon Biological Pathways Underlying the Psychoneurological Symptom Cluster in Cancer Patients
Kim, H.-J., Barsevick, A. M., Fang, C. Y., & Miaskowski, C. (2012) · Cancer Nursing · doi:10.1097/ncc.0b013e318233a811 · Cited by 181
Mesenchymal stroma: Role in osteosarcoma progression
Cortini, M., Avnet, S., & Baldini, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.024 · Cited by 171
Metadata
- Authors
- Rutkowski, P., Kamińska, J., Kowalska, M., Ruka, W., & Steffen, J.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2003-10-29
- Volume
- 84
- Issue
- 3
- Pages
- 151-159
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W1968130822
- Cited by
- 117
- References
- 2
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.